Slides
Page 1
MEDIC 02-08-38 Actinogen Clinical Trials Science Forum 2026 The future of Alzheimer's disease treatment Andrew Udell , Chief Commercial Officer Dr. Dana Hilt , Chief Medical Officer Prof. Marwan Sabbagh , Internationally recognized Alzheimer's disease expert 12 August 2026 02:43 0101010 586 89 253 68 10101010 : 99 : RP
Page 2
Disclaimer This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities. Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. This presentation is not for general distribution or third party reliance or use. This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management in respect of which there is NO guarantee of future performance. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its clinical trials including whether it's technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and global economic conditions. Furthermore, Actinogen's research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward- looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends. To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (Parties) exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or any accompanying, previous or subsequent material or presentation. 2Clinical Trials Science Forum August 2026
Page 3
Clinical Trials Science Forum August 2026 3 3Clinical Trials Science Forum August 2026
Page 5
Alzheimer’s is personal 5Clinical Trials Science Forum August 2026 A disease that touches millions of patients, families and caregivers around the world
Page 6
Alzheimer’s is one of healthcare’s greatest challenges in the western world • 57 million people worldwide were living with dementia in 2021 • Alzheimer’s disease accounts for 60-70% of all dementia cases • Nearly 10 million new cases of dementia occur each year • 139 million people are projected to be living with dementia by 2050 6Clinical Trials Science Forum August 2026 The growing global burden reinforces the need for continued innovation in Alzheimer’s disease
Page 7
A new era in Alzheimer’s disease has dawned • Disease-modifying therapies have begun to reshape the treatment landscape • Blood-based biomarkers have the potential to simplify the diagnosis and identify patients earlier • Scientific understanding continues to expand across multiple biological pathways • Earlier diagnosis and new treatment approaches may improve care for more patients 7Clinical Trials Science Forum August 2026 Progress has begun, but the need for ongoing innovation remains
Page 8
Amyloid is a likely just a small part of the story ... Recent advances have provided hope for some Alzheimer’s patients… … but significant challenges remain: • Clinical benefit can be modest • Current therapies are not appropriate for all patients • Treatment and monitoring can be complex • Alzheimer’s disease is biologically complex and likely requires multiple therapeutic approaches. 8Clinical Trials Science Forum August 2026 New mechanistic approaches are needed to address the diverse needs of patients living with Alzheimer’s disease
Page 9
Neurologists expect the Alzheimer’s landscape to continue evolving • 91% agree there remains a high unmet need for additional disease-modifying therapies • 86% expect the treatment of Alzheimer’s disease to change over the next five years “We’re not going to be just treating patients with an amyloid remover, but also anti-neuroinflammation, mitochondrial enhancers, synaptic enhancers and so on… in order to actually stop or substantially slow the progression of the disease.” --U.S. Neurologist 9Clinical Trials Science Forum August 2026 We are just at the beginning of the journey towards understanding the biology of Alzheimer’s disease
Page 10
What do neurologists value most in Alzheimer’s therapies? Neurologists consistently value therapies that offer: • Meaningful clinical benefit i.e. slowing or halting disease progression • A favorable safety and tolerability profile • Simple, convenient administration • Broader patient eligibility • The potential to complement other therapies. 10Clinical Trials Science Forum August 2026 Future Alzheimer’s therapies will need to deliver meaningful benefit while fitting seamlessly into clinical practice
Page 11
Attributes neurologists value for an Alzheimer’s therapy Attributes valued by neurologists Xanamem profile ✓ Meaningful clinical benefit Encouraging Phase 2 clinical efficacy signals* ✓ Favorable safety and tolerability Generally well tolerated in clinical trials ✓ Convenient administration Once-daily oral tablet ✓ Simplicity of treatment No infusion or routine MRI monitoring required ✓ Potential to complement other therapies Novel mechanism targeting excess brain cortisol, distinct from anti-amyloid therapies 11Clinical Trials Science Forum August 2026 *Based on phase 2 clinical trials. XanaMIA phase 2b/3 topline results anticipated in November 2026 Xanamem’s profile aligns with the characteristics neurologists consider important for future Alzheimer’s therapies
Page 12
A different approach to Alzheimer’s disease Xanamem controls brain cortisol levels Unlike therapies that target amyloid, Xanamem targets excess brain cortisol by inhibiting the enzyme 11β-HSD1 Per extensive scientific literature, reducing excess brain cortisol has the potential to influence several processes associated with Alzheimer’s disease, including: • Cognition and memory • Neuroinflammation • Synaptic function • Tau biology. 12Clinical Trials Science Forum August 2026 Targeting excess brain cortisol represents a unique and promising approach to Alzheimer’s disease
Page 13
The next chapter begins with the XanaMIA trial Pivotal, phase 2b/3 trial in 247 participants with mild-moderate disease Topline results anticipated in November 2026 If successful, Xanamem has potential to: • Expand therapeutic options for patients living with Alzheimer’s disease • Further validate brain cortisol control as a therapeutic mechanism • Contribute to the next generation of Alzheimer's disease treatment. 13Clinical Trials Science Forum August 2026 XanaMIA represents an important milestone for patients, physicians, caregivers, and the future of Alzheimer’s disease treatment
Page 14
Clinical Trials Science Forum August 2026 14 14Clinical Trials Science Forum August 2026
Page 15
Contacts Will Souter CFO & Investor Relations M: +61 402 035 716 E. will.souter@actinogen.com.au Steven Gourlay CEO & Managing Director P: +61 2 8964 7401 E. steven.gourlay@actinogen.com.au Join the Actinogen Investor Hub: https://investors.actinogen.com.au/ 15Clinical Trials Science Forum August 2026